{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/temporomandibular-disorders-tmds/prescribing-information/diazepam/","result":{"pageContext":{"chapter":{"id":"a1e54efb-fced-5ea8-a653-53066beb1ef5","slug":"diazepam","fullItemName":"Diazepam","depth":2,"htmlHeader":"<!-- begin field 393891d1-7b75-4c18-b6b8-5032a42ffc85 --><h2>Diazepam</h2><!-- end field 393891d1-7b75-4c18-b6b8-5032a42ffc85 -->","summary":"","htmlStringContent":"<!-- begin item 3bcaa018-8abb-4268-8ed8-ef7b099483c1 --><!-- end item 3bcaa018-8abb-4268-8ed8-ef7b099483c1 -->","topic":{"id":"c62ead43-22e8-5bf2-b8ed-84185d5f1595","topicId":"2c31b829-99a4-46d4-b910-619f38d2a709","topicName":"Temporomandibular disorders (TMDs)","slug":"temporomandibular-disorders-tmds","lastRevised":"Last revised in December 2016","chapters":[{"id":"3b93c6f8-8e4b-588f-9e56-52afda9aadfb","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"25105bf7-6f28-5338-9aea-733d2ed9daa0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"62dd37e0-afdd-5f75-af0f-de4f7553f406","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"6ff80917-fb76-5a1f-b9bd-97e8d97e614b","slug":"changes","fullItemName":"Changes"},{"id":"35735ab1-08b2-5c7c-9b78-0cb07e83a259","slug":"update","fullItemName":"Update"}]},{"id":"95692e79-70d9-54a3-8d3d-5eee089d99a6","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"95932582-335e-5652-ab4d-365d5ad14e83","slug":"goals","fullItemName":"Goals"},{"id":"e9401bca-91b8-535c-bb2f-921620544c4f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2ff5e194-f0c9-5145-8ebc-a2b22c2211fb","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f8af69c5-5dff-5ab0-8b0d-db2178d63e96","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"49a96e72-3b88-5c75-98f8-87ad4a16d7c6","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"bd4a57c4-6da6-5a1f-9cea-a9edb77ba216","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3cad4541-2d56-5efb-b887-12fcdef2569d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b58b5737-5b1f-53c0-be92-800d51b8b7c0","slug":"definition","fullItemName":"Definition"},{"id":"1a9ad3e1-4253-5a9d-99f9-1e951d41a9d0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"7cadd30c-36e9-5240-8630-49e80b58f784","slug":"causes","fullItemName":"Causes"},{"id":"fe83b9b2-2482-5385-a3e1-5fbb3401fd96","slug":"complications","fullItemName":"Complications"},{"id":"fd13f42f-eb90-5ea8-9515-bb192c9b3178","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"d8f67a17-bb6c-5f2b-95ff-da96b572b6a9","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"41caee7f-ceed-5f25-b339-645035942394","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"5379ddf2-c073-525f-8061-c46b0b3a5ed4","slug":"assessment","fullItemName":"Assessment"},{"id":"5676b33f-5aab-5457-8335-4b008cbe18fe","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"40cace77-bdfa-51e0-87a8-1bb642e476c8","fullItemName":"Management","slug":"management","subChapters":[{"id":"4e37f7fc-294b-5ec0-b8f4-1c9b7fd8c581","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"f5ac4f03-3550-554a-a0d8-4c3a775171e9","fullItemName":"Prescribing Information","slug":"prescribing-information","subChapters":[{"id":"0733e2ed-2f88-5024-a222-b79542882149","slug":"simple-analgesia","fullItemName":"Simple analgesia"},{"id":"a1e54efb-fced-5ea8-a653-53066beb1ef5","slug":"diazepam","fullItemName":"Diazepam"},{"id":"16f82be9-ed34-5e1d-9ff0-001191bc438c","slug":"amitriptyline-gabapentin","fullItemName":"Amitriptyline and gabapentin"}]},{"id":"bd5129d8-4de9-54c0-a546-a57ecca4de60","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"fd619f04-799c-5e7c-97ee-0daf1422f219","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b63026eb-80b7-58ff-9f8c-37580117cd46","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"ebe8f374-d3da-5db4-a3b9-3a4d12748e6c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6b8c2b13-f5ba-59ef-b530-bc1d9c183192","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"99c9ae47-ddad-572f-94ef-5835c39a9fc8","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"62247755-73be-5ca1-ab5c-7f30a66aa173","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d344f327-a5eb-5e8c-9619-908d4299e512","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f5ac4f03-3550-554a-a0d8-4c3a775171e9","slug":"prescribing-information","fullItemName":"Prescribing Information"},"subChapters":[{"id":"2ed15bd4-d161-5cd1-9433-f284e2f1da11","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 1e39fac9-5298-4a82-8fea-a6cd00ce730e --><h3>Adverse effects</h3><!-- end field 1e39fac9-5298-4a82-8fea-a6cd00ce730e -->","summary":"","htmlStringContent":"<!-- begin item b829833f-c092-4caf-a332-a6cd00ce71de --><!-- begin field 5f80729f-4777-4fb8-bffa-a6cd00ce730e --><ul><li><strong>The most common adverse effects</strong> of diazepam relate to its sedative effect and include drowsiness and light-headedness, for example the next day - advise the person that the performance of skilled tasks such as driving may be affected.</li><li><strong>Other adverse effects include:</strong><ul><li>Confusion and ataxia (especially in the elderly), amnesia, muscle weakness.</li><li>Headache, vertigo, tremor, dysarthria, hypotension, decreased libido, erectile dysfunction, gynaecomastia, urinary retention.</li><li>Paradoxical effects such as talkativeness, excitement, irritability, aggression, anti-social behaviour, and suicidal ideation.</li><li>Withdrawal symptoms, for example anxiety, depression, impaired concentration, insomnia, abdominal cramps, palpitations, and perceptual disturbances (such as hypersensitivity to physical, visual, and auditory stimuli). For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/benzodiazepine-z-drug-withdrawal/\">Benzodiazepine and z-drug withdrawal</a>.</li><li>Tolerance and dependence - people who use benzodiazepines longer term can develop tolerance and eventual dependence.</li></ul></li><li><strong>Give the following advice to a person taking diazepam who drives:</strong><ul><li>You should not drive if you feel drowsy, dizzy, unable to concentrate or make decisions.</li><li>It is now an offence to drive if you have more than a specified amount of benzodiazepine in your body whether your driving is impaired or not.</li><li>Roadside drug screening tests have been introduced in the UK since March 2015. These test the saliva for drugs that impair driving. If you have a positive roadside drug test for benzodiazepines, the police may ask you to provide a blood sample to measure the amount of benzodiazepine in your body.</li><li>If you are found to have more than the specified amount of benzodiazepine, as long as your driving is not impaired, you are taking your medicine on the advice of your GP or pharmacist, you will be able to raise a 'statutory defence' and the police may not prosecute you.</li><li>It may be helpful to keep evidence with you while you are driving, that you are taking a benzodiazepine in accordance with medical advice. Suitable evidence may include:<ul><li>Your medication box with the pharmacy label on.</li><li>The other half of your prescription with the list of medicines prescribed by your doctor.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/temporomandibular-disorders-tmds/references/\">Department for Transport, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/temporomandibular-disorders-tmds/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/temporomandibular-disorders-tmds/references/\">BNF 72, 2016</a>]</p><!-- end field 5f80729f-4777-4fb8-bffa-a6cd00ce730e --><!-- end item b829833f-c092-4caf-a332-a6cd00ce71de -->","subChapters":[]},{"id":"b16b3ffc-0f06-5314-886a-93310d14626f","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field a651ebb9-08e0-4d7f-b42b-a6cd00ce5d4b --><h3>Contraindications and cautions</h3><!-- end field a651ebb9-08e0-4d7f-b42b-a6cd00ce5d4b -->","summary":"","htmlStringContent":"<!-- begin item ba0c438a-ebbc-45d2-a46d-a6cd00ce5bd3 --><!-- begin field 03c44413-238d-4c8f-b472-a6cd00ce5d4b --><ul><li><strong>Do not prescribe diazepam to people</strong> <strong>with:</strong><ul><li>Respiratory depression.</li><li>Marked neuromuscular respiratory weakness, such as unstable myasthenia gravis.</li><li>Obstructive sleep apnoea syndrome — symptoms may be aggravated.</li><li>Severe hepatic impairment — the elimination half-life of diazepam may be prolonged; increased risk of coma.</li><li>Phobic or obsessional states; chronic psychosis, hyperkinesis — paradoxical reactions may occur.</li></ul></li><li><strong>Prescribe diazepam with caution to people with:</strong><ul><li>Respiratory disease.</li><li>Muscle weakness and myasthenia gravis — symptoms may be aggravated.</li><li>Organic brain disease.</li><li>Severe renal impairment — increased cerebral sensitivity to diazepam; a reduced dose may be appropriate.</li><li>Dependent, obsessive-compulsive, or avoidant-type personality disorders — may increase the risk of dependency.</li><li>Frailty and the elderly — increased falls risk; a reduced dose may be appropriate.</li><li>A history of drug and/or alcohol misuse or dependency — increased risk of dependency.</li></ul></li><li><strong>Do not prescribe diazepam to pregnant women</strong> unless unavoidable (for example, for seizure control) — risk of neonatal withdrawal symptoms.</li><li><strong>Do not prescribe diazepam to breastfeeding women</strong> if possible — diazepam is excreted in breast milk with the potential to cause infant sedation.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/temporomandibular-disorders-tmds/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/temporomandibular-disorders-tmds/references/\">BNF 72, 2016</a>]</p><!-- end field 03c44413-238d-4c8f-b472-a6cd00ce5d4b --><!-- end item ba0c438a-ebbc-45d2-a46d-a6cd00ce5bd3 -->","subChapters":[]},{"id":"54164901-c0ce-5dee-a8f0-fc724f355a22","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 72122ce1-b467-45f8-a01a-a6cd00ce8a0c --><h3>Drug interactions</h3><!-- end field 72122ce1-b467-45f8-a01a-a6cd00ce8a0c -->","summary":"","htmlStringContent":"<!-- begin item 83fc7ee9-1793-4784-8fa9-a6cd00ce88bd --><!-- begin field e2b33c22-b4ec-413d-841e-a6cd00ce8a0c --><ul><li><strong>The following drug interactions may occur with diazepam:</strong><ul><li><strong>Alcohol and opioids</strong> — advise against concomitant use with diazepam, as they can induce lethal sedation by potentiating the effects of diazepam.</li><li><strong>Antihypertensives, vasodilators, and diuretics —</strong> concomitant use with diazepam may enhance the hypotensive effects of these drugs.</li><li><strong>Drugs that inhibit cytochrome P450 enzyme </strong>(for example cimetidine, ciprofloxacin, azole antifungals, and oestrogens) — avoid concomitant use with diazepam. The metabolism of diazepam is mediated by cytochrome P450 isoenzymes. Concomitant use with these drugs can result in increased serum levels of diazepam leading to a risk of prolonged sedation.</li><li><strong>Drugs that induce cytochrome P450 enzyme</strong> (for example St John's Wort and rifampicin) — cytochrome P450 inducers can accelerate hepatic elimination of diazepam and decrease its action. Dose adjustment of diazepam may be needed.</li><li><strong>HIV protease inhibitors (ritonavir and indinavir)</strong> — concomitant use with diazepam is contraindicated.</li><li><strong>Modafinil</strong> — monitor for adverse effects of diazepam as modafinil may increase the effects of diazepam. Dose adjustment of diazepam may be needed.</li><li><strong>Phenytoin</strong> — monitor phenytoin concentrations as concomitant use with diazepam may increase or decrease serum concentrations of phenytoin.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/temporomandibular-disorders-tmds/references/\">ABPI Medicines Compendium, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/temporomandibular-disorders-tmds/references/\">BNF 72, 2016</a>]</p><!-- end field e2b33c22-b4ec-413d-841e-a6cd00ce8a0c --><!-- end item 83fc7ee9-1793-4784-8fa9-a6cd00ce88bd -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}